Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis

Oncology Reports

Volumn 36, Issue 6, 2016, Pages 3267-3274

  Sang, Xiu Bo ^a   Sun, Kai Xuan ^a   Wang, Li Li ^a   Chen, Shuo ^a   Wu, Dan Dan ^a   Zong, Zhi Hong ^a   Zhao, Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Invasion; Metastasis; Ovarian cancer; RhoC; Stem cells

Indexed keywords

CD133 ANTIGEN; GELATINASE B; MESSENGER RNA; PACLITAXEL; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN, HUMAN;

A2780 CELL LINE; ARTICLE; ASSAY; CANCER RESISTANCE; CANCER STEM CELL; CD117 GENE; CD133 GENE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOFLUORESCENCE; METASTASIS INHIBITION; MIGRATION INHIBITION; MMP9 GENE; MTT ASSAY; ONCOGENE; OVARIAN CANCER CELL LINE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHOC GENE; TRANSWELL ASSAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; METASTASIS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; RHO GTP-BINDING PROTEINS;

EID: 84994553156     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5164     Document Type: Article

References (21)

1. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR and Seamon LG: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120: 612-618, 2012.
2. Bae T, Weon KY, Lee JW, Eum KH, Kim S and Choi JW: Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer. Carcinogenesis 36: 1561-1571, 2015.
3. Yoo YD and Kwon YT: Molecular mechanisms controlling asymmetric and symmetric self-renewal of cancer stem cells. J Anal Sci Technol 6: 28, 2015.
4. Beachy PA, Karhadkar SS and Berman DM: Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331, 2004.
5. Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS One 3: e3077, 2008.
6. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 14: 450-460, 2008.
7. Li F, Tiede B, Massagué J and Kang Y: Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 17: 3-14, 2007.
8. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
9. Vezzoni L and Parmiani G: Limitations of the cancer stem cell theory. Cytotechnology 58: 3-9, 2008.
10. Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer 2: 133-142, 2002.
11. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R and Mak TW: RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19: 1974-1979, 2005.
12. Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q, Merajver SD and Rho C: RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 12: 4485-4490, 2006.
13. Islam M, Sharma S and Teknos TN: RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS One 9: e88527, 2014.
14. Rosenthal DT, Zhang J, Bao L, Zhu L, Wu Z, Toy K, Kleer CG and Merajver SD: RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One 7: e40979, 2012.
15. Chen S, Chen X, Xiu YL, Sun KX, Zhao Y and Zhao Y: Inhibition of ovarian epithelial carcinoma tumorigenesis and progression by microRNA 106b mediated through the RhoC pathway. PLoS One 10: e0125714, 2015.
16. Chen X, Chen S, Xiu YL, Sun KX, Zong ZH and Zhao Y: RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Mol Cancer 14: 31, 2015.
17. Chen S, Wang J, Gou WF, Xiu YL, Zheng HC, Zong ZH, Takano Y and Zhao Y: The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int J Mol Sci 14: 24187-24199, 2013.
18. Lukenda A, Dotlic S, Vukojevic N, Saric B, Vranic S and Zarkovic K: Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. J Clin Pathol 69: 234-239, 2016.
19. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
20. Xie SL, Zhu MG, Chen GF, Wang GY and Lv GY: Effects of Ras homolog gene family, member C gene silencing combined with rapamycin on hepatocellular carcinoma cell growth. Mol Med Rep 12: 5077-5085, 2015.
21. Mitin N, Rossman KL, Currin R, Anne S, Marshall TW, Bear JE, Bautch VL and Der CJ: The RhoGEF TEM4 regulates endothelial cell migration by suppressing actomyosin contractility. PLoS One 8: e66260, 2013.